# Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Source: https://onco.cc/trials/nct05786924/  
OnCo record `nct05786924` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of fOLFIRI (5-FU, leucovorin, irinotecan), cetuximab, panitumumab, gemcitabine and other drugs in colorectal cancer, run by Institut de Recherches Internationales Servier, now recruiting.

## Summary

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies is a phase 1/2, interventional study registered as NCT05786924 by Institut de Recherches Internationales Servier, with a registry enrolment figure of 554 participants, started 2023-04-18 and due to reach its primary completion in 2028-06. Interventions recorded: S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel. Conditions listed: Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D. Primary outcome: Dose Escalation: Incidence of dose-limiting toxicities (DLTs); Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs); Dose Optimization/Expansion: Objective response (OR). Colorectal eligibility wording from the registry: "* Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations". Sites: Australia, China, Denmark, France, Hong Kong, Italy, Japan, Spain, United Kingdom, United States. United Kingdom sites listed: 3. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05786924
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
- Sponsor: Institut de Recherches Internationales Servier
- Enrolled: 554

## Notes

- UK sites (registry): University College London Hospital (London); Hammersmith Hospital (London); The Christie NHS Foundation Trust (Manchester).

## Sources

- ClinicalTrials.gov NCT05786924: https://clinicaltrials.gov/study/NCT05786924

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Panitumumab](https://onco.cc/drugs/panitumumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05786924.json